Therapeutic Solutions International (Therapeutic Solutions International) Total Liabilities : $2.01 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Total Liabilities?

Therapeutic Solutions International's Total Liabilities for the quarter that ended in Dec. 2023 was $2.01 Mil.

Therapeutic Solutions International's quarterly Total Liabilities increased from Jun. 2023 ($2.00 Mil) to Sep. 2023 ($2.17 Mil) but then declined from Sep. 2023 ($2.17 Mil) to Dec. 2023 ($2.01 Mil).

Therapeutic Solutions International's annual Total Liabilities declined from Dec. 2021 ($2.52 Mil) to Dec. 2022 ($2.22 Mil) and declined from Dec. 2022 ($2.22 Mil) to Dec. 2023 ($2.01 Mil).

Therapeutic Solutions International Total Liabilities Historical Data

The historical data trend for Therapeutic Solutions International's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International Total Liabilities Chart

Therapeutic Solutions International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2.35

2.38

2.52

2.22

2.01

Therapeutic Solutions International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															2.22	2.39	2.00	2.17	2.01

Therapeutic Solutions International Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Therapeutic Solutions International's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.9	+	(0.111	+	-0.0010000000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.01

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3.292	-	1.282
	=	2.01

Therapeutic Solutions International's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.9	+	(0.111	+	-0.0010000000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.01

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	3.292	-	1.282
	=	2.01

Therapeutic Solutions International Total Liabilities Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

701 Wild Rose Lane, Elk City, ID, USA, 83525

Website

https://www.therapeuticsolutionsint.com

Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

Executives

Thomas Ichim	director	211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg	officer: CFO	1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon	director, officer: Chairman, President, CEO	4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman	officer: VP, Training & Education	2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd	director, 10 percent owner	PO BOX 2145, RANCHO SANTA FE CA 92067